Compare Quest Diagnostics Inc (DGX) vs Vanguard Mega Cap Growth ETF (MGK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Vanguard Mega Cap Growth ETF — how do they compare? Quest Diagnostics Inc trades at $204.84 (market cap $22.80B), while Vanguard Mega Cap Growth ETF trades at $88.84. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Vanguard Mega Cap Growth ETF pays none. Which is the better fit depends on your goals.
| DGX | MGK | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $216.02 | $92.06 |
52-Week Low | $166.42 | $70.70 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
MGK (Vanguard Mega Cap Growth ETF) trades at $87.69, down 1.54% today amid a bearish technical signal. The ETF maintains a concentrated portfolio of 69 large-cap growth stocks with heavy technology exposure and a low 0.05% expense ratio. Recent developments include a 1:5 stock split effective April 21, 2026, and potential addition of SpaceX following its recent IPO.
The ETF's concentrated mega-cap growth strategy offers strong long-term return potential but carries sector concentration risk. Technical indicators suggest near-term consolidation while fundamental strength in technology holdings supports the bullish long-term thesis. Investors should weigh the ETF's historical outperformance against its vulnerability to tech sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →
